Slingshot Insights | Lly Overview

LLY Overview

Upcoming Projects (LLY)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (LLY)

Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 24, 2024 at 04:56 PM EDT
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi October 2024
Tickers: BIIB, LLY
Executed On: Oct 18, 2024 at 02:13 PM EDT
Discussing Lilly's QWINT-1 and QWINT-3 Phase 3 data evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes
Ticker: LLY
Executed On: Sep 13, 2024 at 09:00 AM EDT
A Second View: Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Tickers: AVXL, LLY, BIIB
Executed On: Aug 28, 2024 at 03:30 PM EDT
Discussing the potential of INV-202 (Monlunabant), a CB1 antagonist currently in development by Novo Nordisk for weight loss
Tickers: NVO, LLY, CRBP
Executed On: Aug 20, 2024 at 10:30 AM EDT
Digging into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Tickers: LLY, NVO
Executed On: Aug 14, 2024 at 01:00 PM EDT
Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Tickers: AVXL, LLY, BIIB
Executed On: Aug 06, 2024 at 10:30 AM EDT
Discussing the SURMOUNT-OSA phase 3 clinical trial of tirzepatide in patients with obstructive sleep apnea and obesity
Tickers: LLY, NVO
Executed On: Aug 06, 2024 at 10:00 AM EDT
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic July 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Aug 01, 2024 at 10:42 AM EDT
Looking at the impact of GLP-1 weight loss medications on the Continuous Glucose Monitoring (CGM) Market in Type 2 Diabetes
Tickers: DXCM, SENS, ABT, MDT, LLY, NVO
Executed On: Jul 30, 2024 at 12:00 PM EDT
Discussing the potential use of PD-L1 agonists in treating Rheumatoid Arthritis
Tickers: LLY, ANAB
Executed On: Jul 29, 2024 at 10:00 AM EDT
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi July 2024
Tickers: BIIB, LLY
Executed On: Jul 23, 2024 at 02:07 PM EDT
Exploring the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy for obesity and type 2 diabetes
Tickers: GUTS, NVO, LLY
Executed On: Jul 19, 2024 at 02:30 PM EDT
Discussing the IRAK4 degrader KT-474/SAR444656 from Kymera/Sanofi and the potential in HS (Hidradenitis suppurativa) and AD (atopic dermatitis)
Tickers: KYMR, REGN, LLY, SNY, ABBV
Executed On: Jul 18, 2024 at 11:00 AM EDT
Discussing current treatment options for CLL and the potential of Nurix Therapeutics' NX-5948, a BTK degrader
Tickers: NRIX, ABBV, BGNE, AZN, LLY
Executed On: Jul 12, 2024 at 10:00 AM EDT
A Second Opinion: Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jul 09, 2024 at 04:30 PM EDT
Discussing the topline data from Lilly's SURMOUNT-OSA Phase 3 trial on tirzepatide for patients with Obstructive Sleep Apnea and the impact on the use of CPAP
Tickers: LLY, PHG, RMD
Executed On: Jul 03, 2024 at 02:00 PM EDT
Discussing the recent MASH/NASH data presented at the 2024 EASL Congress with a focus on Madrigal's Rezdiffra (resmetirom) and Lilly's tirzepatide
Tickers: MDGL, LLY
Executed On: Jun 28, 2024 at 01:00 PM EDT
Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jun 27, 2024 at 10:30 AM EDT
Discussing the potential of Lilly's Donanemab based on the Phase 3 TRAILBLAZER-ALZ 2 study after FDA adcomm backs drug
Ticker: LLY
Executed On: Jun 20, 2024 at 10:40 AM EDT
A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 14, 2024 at 11:00 AM EDT
Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 13, 2024 at 02:40 PM EDT
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 18, 2024 at 03:17 PM EDT
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi April 2024
Tickers: BIIB, LLY
Executed On: Apr 18, 2024 at 11:12 AM EDT
A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Tickers: NVO, LLY
Executed On: Mar 22, 2024 at 09:30 AM EDT
Exploring the Breakthroughs in Early Alzheimer's Disease: Discussing Leqembi with a Prescriber & Examining the TRAILBLAZER-ALZ 2 Phase 3 Study ahead of Early 2024 PDUFA Decision
Tickers: BIIB, LLY, ESALF, EII.XFRA
Executed On: Feb 22, 2024 at 02:30 PM EST
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 22, 2024 at 01:24 PM EST
Discussing the potential of Regeneron's otoferlin gene therapy, currently being investigated in the Phase 1/2 CHORD trial for patients with genetic hearing loss
Tickers: REGN, AKUS, LLY
Executed On: Dec 13, 2023 at 01:00 PM EST
Discussing the impact of GLP-1 agonists on patient eligibility for bariatric surgeries and the need for new surgical systems
Tickers: ISRG, NVO, LLY, MDT
Executed On: Dec 08, 2023 at 01:15 PM EST
A Payor Perspective: Discussing reimbursement for GLP-1 drugs based on cardiovascular benefits with a focus on the SELECT trial
Tickers: NVO, LLY
Executed On: Dec 06, 2023 at 02:00 PM EST
Quarterly Survey: Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 26, 2023 at 04:59 PM EDT
A Third Perspective: Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 20, 2023 at 03:45 PM EDT
A Second Perspective: Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 16, 2023 at 01:00 PM EDT
Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 13, 2023 at 12:00 PM EDT
A second look: Discussing the potential of Lilly's Peresolimab in treating Rheumatoid Arthritis with a focus on the Phase 2 trial data
Tickers: LLY, ANAB
Executed On: Sep 26, 2023 at 02:00 PM EDT
Discussing the potential of Lilly's Peresolimab in treating Rheumatoid Arthritis with a focus on the Phase 2 trial data
Tickers: LLY, ANAB
Executed On: Sep 18, 2023 at 04:00 PM EDT
A Second Look: Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with an endocrinologist
Tickers: NVO, LLY
Executed On: Sep 13, 2023 at 11:00 AM EDT
A Second Look: Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 28, 2023 at 03:00 PM EDT
Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with a cardiologist
Tickers: NVO, LLY, AZN
Executed On: Aug 22, 2023 at 02:15 PM EDT
Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 11, 2023 at 10:30 AM EDT
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jul 25, 2023 at 05:46 PM EDT
Discussing private and commercial payor reimbursement strategies in the US for obesity drugs such as semaglutide and tirzepatide
Tickers: NVO, LLY
Executed On: Jul 20, 2023 at 11:00 AM EDT
Examining the potential of Lilly's GIP/GLP-1/Glucagon Receptor Tri-agonist, retatrutide with a focus on the Phase 2 results in obesity presented at the ADA 2023 Conference
Ticker: LLY
Executed On: Jul 05, 2023 at 01:00 PM EDT
A Second Opinion: Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection
Tickers: RHHBY, LLY
Executed On: Jun 16, 2023 at 04:00 PM EDT
Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection
Tickers: RHHBY, LLY
Executed On: Jun 14, 2023 at 03:00 PM EDT
A Second Look: Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi
Tickers: LLY, BIIB
Executed On: May 18, 2023 at 04:30 PM EDT
A discussion of the KRAS G12C NSCLC landscape, including commercial assets and the AACR data updates from GDC-6036, LY3537982, and IBI351.
Tickers: AMGN, MRTX, RVMD, LLY, RHHBF
Executed On: May 16, 2023 at 06:30 PM EDT
Digging into the Alzheimer's Landscape with a focus on Lilly's recent TRAILBLAZER-ALZ 2 Phase 3 study compared to Biogen's Leqembi
Tickers: LLY, BIIB
Executed On: May 04, 2023 at 02:00 PM EDT
Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023
Tickers: LLY, NVO, AZN
Executed On: Apr 12, 2023 at 02:43 PM EDT
Examining Eli Lilly's Jaypirca (pirtobrutinib) in light of the FDA Approval for mantle cell lymphoma
Ticker: LLY
Executed On: Mar 23, 2023 at 01:00 PM EDT
Discussing the treatment landscape for alopecia areata with a focus on therapies from Incyte, Concert, Lilly, Pfizer, and Equillium
Tickers: INCY, CNCE, LLY, EQ, PFE
Executed On: Mar 08, 2023 at 01:30 PM EST
Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide January 2022
Ticker: LLY
Executed On: Feb 07, 2023 at 03:49 PM EST
Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes
Tickers: LLY, VTRSV, SNY
Executed On: Jan 05, 2023 at 04:30 PM EST
A Second View: Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes
Tickers: LLY, SNY, VTRSV
Executed On: Jan 05, 2023 at 01:30 PM EST
A Second View: Discussing LLY's Mounjaro (tirzepatide) as a weight loss treatment for patients with obesity and other overweight-related health problems
Ticker: LLY
Executed On: Dec 05, 2022 at 11:00 AM EST
Another view: A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 23, 2022 at 11:00 AM EST
A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 18, 2022 at 03:00 PM EST
Discussing LLY's Mounjaro (tirzepatide) as a weight loss treatment for patients with obesity and other overweight-related health problems
Ticker: LLY
Executed On: Nov 14, 2022 at 11:30 AM EST
A look at the recent approval of Eli Lilly and Incyte's Olumiant (baricitinib) and potential use in alopecia areata
Tickers: LLY, INCY
Executed On: Jun 17, 2022 at 02:45 PM EDT
A look at tirzepatide's Phase 3 data in Type 2 Diabetes and Obesity in comparison with semaglutide and other GLP-1's, and examining the potential market opportunity for tirzepatide in Type 2 Diabetes and Obesity
Tickers: LLY, NVO
Executed On: May 05, 2022 at 03:00 PM EDT
A look at the pending PDUFA of tirzepatide and how it may compare to Rybelsus (semaglutide) and the Type 2 diabetes space as a whole
Tickers: LLY, NVO
Executed On: Apr 21, 2022 at 04:00 PM EDT

Expired Projects (LLY)

Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022
Evaluating the Chances of Approval and Market Potential for Radius Health's (RDUS) Abaloparatide-SC for Postmenopausal Women with Osteoporosis
Tickers: RDUS, AMGN, LLY
Execute By: May 09, 2017
Discussing the Landscape of the Injectable Long-Acting Insulin Market for Merck's Glargine (MK-1293) in Type 1 & 2 Diabetes Following Expected April PDUFA
Tickers: MRK, SNY, LLY, NVO
Execute By: Apr 14, 2017
To see if we can get the specific DOJ requests to Pharma companies on drug pricing. These investigations have been confirmed in 10q filings.
Tickers: MRK, VRX, LLY
Execute By: Mar 04, 2016

Upcoming & Overdue Catalysts (LLY)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (LLY)

Eli Lilly's (LLY) LIBRETTO-001 Phase 1/2 trial of Selpercatinib (LOXO-292) shows a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Tickers: LLY, LOXO
Occurred on: Sep 09, 2019
Lilly's(LLY) Mirikizumab in Crohn's disease Phase 2 data due at DDW meeting 18-21 May, 2019
Ticker: LLY
Occurred on: May 21, 2019
Pfizer (PFE) And Lilly (LLY) Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab at 16-weeks For The Treatment Of Osteoarthritis (OA) Pain
Tickers: PFE, LLY
Occurred on: Jul 18, 2018
Eli Lilly's (LLY) Galcanezumab Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache Data Presented
Ticker: LLY
Occurred on: May 15, 2018
Eagle Pharma's (EGRX) NDA for Liquid Version of Lilly's (LLY) Alimta Granted PDUFA Date of October 30th
Tickers: EGRX, LLY
Occurred on: Oct 27, 2017
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017
FDA Decision on Baricitinib Expected April 19 2017
Tickers: INCY, LLY
Occurred on: Apr 14, 2017
Phase 3 MONARCH 2 Data Evaluating Abemaciclib in Patients with Relapsed/Refractory HR+/HER2- Breast Cancer
Ticker: LLY
Occurred on: Mar 20, 2017
Lilly's (LLY) Diabetes Med Trulicity Now Includes Label for Combination with Basal Insulin in Adults with Type 2 Diabetes
Ticker: LLY
Occurred on: Feb 08, 2017
U.S Court of Appeals Upholds Decision in Lilly's (LLY) Favor Regarding Patent for Alimta Vitamin Regimen
Ticker: LLY
Occurred on: Jan 12, 2017
The first FDA-approved follow-on insulin glargine treatment, BASAGLAR will be available in the U.S. starting on December 15, 2016
Ticker: LLY
Occurred on: Dec 15, 2016
Lilly (LLY) Presents NeoMONARCH Phase 2 Data On Abemaciclib In Early-Stage Breast Cancer
Ticker: LLY
Occurred on: Dec 08, 2016
FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
Ticker: LLY
Occurred on: Dec 02, 2016
Solanezumab Phase III Alzheimer's data (EXPEDITION-3) expected year end 2016
Tickers: BIIB, LLY
Occurred on: Nov 23, 2016
Lilly (LLY)'s Clinical Efficacy, Safety and Patient-Reported Outcomes Data of Baricitinib in Patients with Rheumatoid Arthritis will be presented at 2016 American College of Rheumatology Annual Meeting, November 11-16, 2016
Ticker: LLY
Occurred on: Nov 14, 2016
Jardiance (Empagliflozin) Consistently Reduced The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes Regardless Of The Type Of Cardiovascular Disease At Baseline
Ticker: LLY
Occurred on: Nov 13, 2016
Decision on Lilly's (LLY) Olaratumab in Soft Tissue Sarcoma Expected From European Medicines Agency By End of November
Ticker: LLY
Occurred on: Oct 19, 2016
Lilly's (LLY) Lartruvo Approved by FDA by Soft Tissue Sarcoma
Ticker: LLY
Occurred on: Oct 19, 2016
Lilly (LLY) and Boehringer Ingelheim's Glyxambi Recommended for Approval by European Ad Comm for Type 2 Diabetes
Tickers: LLY, Boehringer Ingelheim
Occurred on: Sep 16, 2016
Lilly's (LLY) Olaratumab + Doxorubicin in Soft Tissue Sarcoma Recommended for Approval by European Ad Comm
Ticker: LLY
Occurred on: Sep 16, 2016
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Tickers: AZN, LLY
Occurred on: Aug 22, 2016
U.S. FDA expands indication for type 2 diabetes treatment Synjardy (empagliflozin/metformin hydrochloride) to include treatment-naïve adults
Ticker: LLY
Occurred on: Jul 19, 2016
Jardiance (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
Ticker: LLY
Occurred on: Jun 14, 2016
Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)
Tickers: INCY, LLY
Occurred on: Jun 09, 2016
Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA (pemetrexed) and CYRAMZA (ramucirumab) with Merck's KEYTRUDA (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer
Ticker: LLY
Occurred on: Jun 05, 2016
Data for Phase 2 MONARCH 1 Trial of Abemaciclib Expected mid-2016
Ticker: LLY
Occurred on: Jun 03, 2016
FDA Rolling Submission of Olaratumab Expected to be Complete By End of H1 of 2016
Ticker: LLY
Occurred on: May 04, 2016
FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma
Ticker: LLY
Occurred on: May 04, 2016
Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease
Tickers: LLY, AZN
Occurred on: Apr 08, 2016
Lilly to Present Data from Phase 3 Studies on Ixekizumab in Psoriasis and Psoriatic Arthritis
Ticker: LLY
Occurred on: Apr 07, 2016
Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics
Tickers: LLY, INCY
Occurred on: Mar 31, 2016
Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold
Tickers: PFE, LLY
Occurred on: Mar 23, 2016
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Mar 22, 2016
Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept
Ticker: LLY
Occurred on: Mar 07, 2016
Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Mar 07, 2016
Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Mar 04, 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Feb 26, 2016
UK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
Ticker: LLY
Occurred on: Feb 12, 2016
Lilly-connected Chinese firm loses five years of financial documents in theft; Lilly's Elanco animal health division invested ~$100M in the company in 2013
Tickers: LLY, CAL:SP
Occurred on: Dec 30, 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly to develop drugs based on ENHANZE
Tickers: HALO, LLY
Occurred on: Dec 21, 2015
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Tickers: LLY, ABBV
Occurred on: Nov 08, 2015
Ignyta (RXDX) Secures Exclusive Global License to Lilly's (LLY) Oral Cancer Drug Candidate Taladegib for ~$53 Million plus an equity investment of $30mm in RXDX
Tickers: RXDX, LLY
Occurred on: Nov 08, 2015
Lilly (LLY) and Incyte (INCY) Announce Data from Phase 3 RA-BEGIN Study Demonstrating Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Patients Treated With Baricitinib Compared with Adalimumab
Tickers: INCY, ABBV, LLY
Occurred on: Nov 07, 2015
Merck (MRK) Receives Inquiries Over Certain Aspects of Drug Pricing
Tickers: MRK, VRX, LLY, Turing
Occurred on: Oct 19, 2015
Eli Lilly (LLY) Announces Positive Top-Line Results From Long Term Study EMPA-REG OUTCOME Evaluating Jardiance in Adults With Type 2 Diabetes
Ticker: LLY
Occurred on: Sep 25, 2015
Lilly (LLY) Receives Inquiries Over Certain Aspects of Drug Pricing (Date is an estimate for "September")
Tickers: LLY, VRX, MRK
Occurred on: Sep 15, 2015
LLY Expects Alzheimer's Drug Solanezumab EXPEDITION-2 Data Readout Early 2014
Ticker: LLY
Occurred on: Jan 23, 2014
Top-Line Results on Solanezumab Phase 3 Clinical Trial in Patients with Alzheimer's Disease
Ticker: LLY
Occurred on: Apr 25, 2012

Strategic Initiatives (LLY)

Lilly (LLY) Completes Acquisition of Dermira (DERM)
Tickers: LLY, DERM
Announcement Date: Feb 20, 2020
Eli Lilly to Acquire AurKa Pharma
Ticker: LLY
Announcement Date: May 14, 2018
Juno Therapeutics Signs Licensing Agreement with Lilly to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
Tickers: JUNO, LLY
Announcement Date: Dec 06, 2017
Eli Lilly (LLY) Acquires CoLucid Pharmaceuticals (CLCD) for ~$960MM Cash
Ticker: LLY
Announcement Date: Jan 18, 2017
Lilly (LLY) and Merck (MRK) Expand Existing Oncology Collaboration, Agree to Evaluating Lartruvo + Keytruda in Advanced/Metastatic Soft Tissue Sarcoma
Tickers: LLY, MRK
Announcement Date: Jan 11, 2017
Lilly's (LLY) Elanco Unit Acquires Boehringer Ingelheim's Rabies Vaccine Portfolio for $885M
Tickers: LLY, Boehringer Ingelheim, Vetmedica, Elanco
Announcement Date: Oct 05, 2016
Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer
Tickers: LLY, Boehringer Ingelheim
Announcement Date: Jul 13, 2016
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool
Tickers: LLY, RHHBY
Announcement Date: Jan 27, 2016